STK17A Antibody

What is STK17A and what is its biological significance?

STK17A (Serine/Threonine Kinase 17A) is a protein kinase that has been identified as a direct target of the p53 tumor suppressor pathway. It plays important roles in modulating reactive oxygen species (ROS) and in cellular responses to DNA damage . STK17A functions within multiple cellular pathways, with particularly significant roles observed in:

• DNA damage response mechanisms

• Apoptotic signaling pathways

• Oxidative stress regulation

• Cell proliferation control

• Migration and invasion processes in cancer cells

STK17A is distinct from its paralog STK17B, with each having separate functional implications in cellular processes . Recent research indicates that STK17A expression is frequently dysregulated in various cancer types, suggesting its importance in tumor biology and potential utility as a prognostic marker .

How does STK17A antibody detection compare across different experimental platforms?

STK17A detection methodologies vary depending on the experimental platform and research question. The most commonly used detection methods include:

When working with STK17A antibodies, researchers should validate specificity using appropriate controls, including STK17A-overexpressing and knockdown cell lines as demonstrated in multiple studies . The quality and specificity of commercially available antibodies can vary significantly, making validation critical for experimental success.

What are the validated approaches for STK17A gene manipulation in experimental models?

Based on published methodologies, researchers have successfully employed several approaches to manipulate STK17A expression:

• Overexpression systems: Plasmid vectors containing the STK17A gene inserted into the BamHI and XhoI sites have been successfully used to generate overexpression models . These constructs should be sequence-confirmed prior to transfection.

• Knockdown strategies: Short hairpin RNA (shRNA) targeting STK17A has been effectively used to generate stable knockdown cell lines . Multiple published studies confirm the functional effects of such knockdown on cell proliferation, migration, and chemosensitivity.

• Reporter constructs: STK17A promoter-linked luciferase reporters (STK-TK-Luc) can be generated to study transcriptional regulation . Site-directed mutagenesis of p53 response elements (p53REs) within these constructs allows for investigation of regulatory mechanisms.

• CRISPR-Cas9 editing: While not explicitly detailed in the provided references, contemporary research increasingly employs CRISPR-Cas9 for targeted STK17A modification.

Transfection efficiency varies between cell lines; therefore, optimization of transfection conditions is recommended for each experimental model.

How is STK17A expression correlated with cancer prognosis and clinicopathological features?

STK17A expression has significant correlations with several clinicopathological parameters, particularly in gastric cancer. The data from tissue microarray analysis of 102 gastric cancer samples revealed:

Research indicates that STK17A assessment may provide valuable prognostic information beyond traditional clinicopathological parameters, particularly for stratifying patients into risk groups.

What methodologies are recommended for studying STK17A in relation to epithelial-mesenchymal transition (EMT)?

STK17A has been shown to regulate gastric cancer cell migration via epithelial-mesenchymal transition (EMT) mechanisms. To effectively study this relationship, researchers have employed the following methodologies:

• Wound healing assays: Cells overexpressing or with knockdown of STK17A are cultured to confluence, and a "wound" is created by scratching the monolayer. Migration rate is monitored by measuring wound closure over time .

• Transwell migration assays: These provide quantitative assessment of the migratory capacity of cells with modified STK17A expression .

• Western blot analysis of EMT markers: Expression of key EMT markers including:

  • E-cadherin (epithelial marker, decreased in EMT)

  • N-cadherin (mesenchymal marker, increased in EMT)

  • Vimentin (mesenchymal marker, increased in EMT)

Research has demonstrated that STK17A overexpression significantly increases the expression of N-cadherin and vimentin while inhibiting E-cadherin expression. Conversely, STK17A knockdown produces the opposite effect , confirming its regulatory role in EMT.

For comprehensive assessment of STK17A's role in EMT, combining these functional assays with molecular analyses provides the most robust experimental approach.

How does STK17A function in chemotherapy resistance mechanisms?

STK17A has emerging significance in chemotherapy response modulation:

• Cisplatin sensitivity: STK17A has been identified as a modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells. Knockdown of STK17A conferred resistance to cisplatin-induced growth suppression and apoptotic cell death .

• Mechanism of resistance: STK17A knockdown is associated with up-regulation of detoxifying and antioxidant genes, including metallothioneins MT1H, MT1M, and MT1X, which have been previously implicated in cisplatin resistance .

• Cross-resistance patterns: STK17A exhibits low expression in acquired drug-resistant cell phenotypes that are resistant to oxaliplatin and 5-fluorouracil. In malignant melanoma cells (MeWo cell line), STK17A has been associated with cross-resistance to DNA-damaging drugs .

• Reactive oxygen species (ROS) modulation: STK17A knockdown results in decreased cellular reactive oxygen species, whereas STK17A overexpression increases ROS levels . This suggests that STK17A influences chemotherapy sensitivity partly through ROS regulation.

These findings suggest that STK17A expression status could potentially serve as a predictive biomarker for chemotherapy response, particularly for platinum-based and DNA-damaging agents.

What are the validated protocols for immunohistochemical detection of STK17A in tissue samples?

For effective immunohistochemical (IHC) staining of STK17A in tissue samples, researchers should follow this validated protocol derived from published methodologies:

• Tissue preparation:

  • Cut 4-μm sections from paraffin-embedded tissue blocks onto adhesion slides

  • Dry slides in thermostat oven for 2 hours at 65°C

• Deparaffinization and rehydration:

  • Deparaffinize sections in xylene

  • Rehydrate through graded ethanol series

• Antigen retrieval:

  • Heat sections in 0.1 mol/L citrate buffer solution (pH 6.0) in a microwave oven for approximately 15 minutes

  • Allow to cool to room temperature

• Blocking and primary antibody incubation:

  • Wash sections in PBS

  • Block in 10% goat serum for 10 minutes at room temperature

  • Incubate with primary anti-STK17A polyclonal antibody (1:150 dilution; e.g., ab97530, Abcam) overnight at 4°C in humidity chamber

• Secondary antibody and detection:

  • Incubate with biotin-labeled goat anti-rabbit IgG (1:100) at room temperature for 30 minutes

  • Apply diaminobenzidine for color development (1 minute at room temperature)

  • Counterstain with hematoxylin for 2 minutes at room temperature

For scoring, IHC results can be evaluated by assessing both staining intensity and percentage of positive cells, calculating a composite score that correlates with clinical parameters.

What strategies should be employed to validate STK17A antibody specificity?

Rigorous validation of STK17A antibody specificity is critical for experimental reliability. Recommended validation strategies include:

• Positive and negative control tissues/cells:

  • Use tissues/cells known to express high levels of STK17A as positive controls

  • Use STK17A-knockdown cell lines as negative controls

• Western blot validation:

  • Confirm antibody detects a single band of appropriate molecular weight

  • Compare results from multiple antibody sources if possible

  • Include STK17A-overexpressing and knockdown cells as controls

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide before application

  • This should abolish specific staining

• Genetic validation:

  • Compare antibody signals in wild-type vs. STK17A-knockout or knockdown models

  • Observed signal should be significantly reduced in knockout/knockdown samples

• Cross-reactivity assessment:

  • Evaluate potential cross-reactivity with related protein STK17B

  • Particularly important since STK17A and STK17B share structural similarities

Documentation of these validation steps significantly enhances the reliability and reproducibility of experimental results with STK17A antibodies.

What are the recommended methodologies for assessing STK17A's impact on cancer cell proliferation?

Based on published research, the following methodologies have proven effective for investigating STK17A's role in cancer cell proliferation:

How can researchers effectively analyze STK17A's role in signaling pathway modulation?

To effectively analyze STK17A's role in signaling pathway modulation, researchers should consider:

• Phosphoproteomic analysis:

  • Identifies downstream substrates and signaling events

  • Similar approaches to those used for STK17B have identified MLC2 as a substrate

  • Enables mapping of STK17A-dependent phosphorylation networks

• Western blot analysis of pathway components:

  • Assess changes in key signaling molecules (activated/phosphorylated forms)

  • Examine effects on p53 pathway components given STK17A's identification as a p53 target

  • Analyze EMT pathway components (E-cadherin, N-cadherin, vimentin)

• Gene expression analysis:

  • RNA-sequencing or microarray analysis of cells with modified STK17A expression

  • Can reveal broader transcriptional networks regulated by STK17A

  • Previous research identified upregulation of detoxifying and antioxidant genes (metallothioneins) after STK17A knockdown

• ROS measurement:

  • Given STK17A's role in ROS modulation, measurement of cellular ROS levels

  • STK17A knockdown decreases ROS, while overexpression increases ROS

• Reporter assays:

  • Luciferase reporter constructs to examine transcriptional activation of pathways

  • STK-TK-Luc and mutated versions have been used to study p53 regulation of STK17A

Integration of these methodologies provides comprehensive insight into STK17A's signaling functions and regulatory networks, beyond simple expression correlations.

How does STK17A compare to STK17B in research applications and therapeutic potential?

While both STK17A and STK17B are serine/threonine kinases with structural similarities, important distinctions have been observed:

STK17B has been more extensively explored as a direct therapeutic target, with inhibitors showing promise in enhancing T cell responses and potential synergy with immune checkpoint inhibitors. Meanwhile, STK17A research has focused more on its prognostic value and biological functions in cancer progression.

Future research might benefit from:

• Comparative studies examining the interplay between STK17A and STK17B

• Development of selective STK17A inhibitors

• Exploration of STK17A as an immunotherapy target, similar to STK17B

• Investigation of potential redundancy or compensation between these paralogs

What are the emerging methodologies for studying STK17A in patient-derived models?

Emerging methodologies for studying STK17A in patient-derived models include:

• Patient-derived organoids (PDOs):

  • Three-dimensional culture systems that better recapitulate tumor heterogeneity

  • Allow assessment of STK17A expression, localization, and function in more physiologically relevant models

  • Enable testing of STK17A manipulation in personalized medicine approaches

• Patient-derived xenografts (PDXs):

  • Maintain tumor heterogeneity and microenvironment interactions

  • Useful for in vivo validation of STK17A's prognostic significance observed in clinical samples

  • Allow testing of potential STK17A-targeting strategies in models that better reflect human disease

• Single-cell analysis technologies:

  • Single-cell RNA sequencing to assess STK17A expression heterogeneity within tumors

  • Correlation of STK17A expression with specific cell states or subpopulations

  • Mapping of STK17A expression to spatial context within tumor architecture

• CRISPR-Cas9 gene editing in primary patient samples:

  • Direct manipulation of STK17A in patient-derived cells

  • Assessment of effects on proliferation, migration, and drug sensitivity

  • Validation of findings from established cell lines in primary models

These emerging methodologies offer opportunities to bridge the gap between basic research findings and clinical applications, potentially accelerating the translation of STK17A-related discoveries into therapeutic strategies.

What are promising directions for STK17A-based therapeutic development?

Based on current understanding of STK17A biology, several promising therapeutic directions emerge:

• STK17A as a prognostic biomarker:

  • Development of standardized IHC-based assays for clinical use

  • Integration with other biomarkers for improved patient stratification

  • Correlation with treatment response to guide therapy selection

• STK17A modulation for chemosensitization:

  • Given STK17A's role in chemotherapy resistance, its targeting could enhance response to platinum agents and 5-fluorouracil

  • Focus on combination strategies with established chemotherapeutics

• Small molecule inhibitor development:

  • Drawing from successful STK17B inhibitor development

  • Design of selective STK17A inhibitors to target cancer cells showing STK17A dependency

  • Potential for dual STK17A/B inhibitors with broader applications

• EMT pathway targeting:

  • Given STK17A's role in promoting EMT , targeting this pathway could reduce metastatic potential

  • Focus on interrupting STK17A-mediated upregulation of N-cadherin and vimentin

• ROS modulation strategies:

  • Exploiting STK17A's role in ROS regulation

  • Combining STK17A targeting with ROS-modulating agents for synergistic effects